India, July 30 -- The Government of India has issued a release:
The Council of Scientific and Industrial Research (CSIR) has been consistently promoting research, innovation, and technology development in healthcare and pharmaceutical technologies through a range of initiatives. These include: (i) research and development collaborations with industry and academia; (ii) technology transfer and licensing to industry; (iii) consultancy services for industrial partners; (iv) testing and analytical services for startups, MSMEs, and academic institutions; (v) skill development and capacity-building programmes for industry and academia; (vi) biological screening, including in vitro and in vivo assays, for research and industrial applications; (vii) advanced sequencing facilities and research infrastructure for Next-Generation Sequencing (NGS); (viii) diagnostic and therapeutic research for rare diseases and clinical genomics through the GUaRDIAN Consortium (Genomics for Understanding Rare Diseases: India Alliance Network) and GOMED (Genomics and other Omics technologies for Enabling Medical Decisions) programme; (ix) population genomics initiatives under the IndiGen and GenomeIndia programmes; and (x) specialised training programmes for clinicians and medical professionals in molecular medicine and genomics. In addition, CSIR provides sustained support to its constituent laboratories through its dedicated 'Healthcare Theme' by funding basic research, translational research, and mission-mode projects aimed at strengthening scientific research, innovation, technology development, and translation in the healthcare and pharmaceutical sectors.
Brief details of the progress made in the development of significant affordable pharmaceutical technologies and treatment for major diseases by CSIR are at Annexure-I.
CSIR has been actively promoting the translation of research outcomes into societal and industrial applications through a comprehensive technology transfer and commercialization ecosystem. Its constituent laboratories engage proactively with industry, academia, startups, MSMEs, and other stakeholders through industry-academia interactions, technology showcases, consultancy and technical services, dissemination of information on R&D capabilities, and participation in national and international technology exhibitions.
CSIR facilitates technology licensing and collaborative R&D on mutually agreed terms and conditions, supported by robust intellectual property management through patents and know-how protection. CSIR has successfully transferred several technologies related to public health services. CSIR also collaborates with industry partners from the early stages of technology development to facilitate seamless commercialization and adopts differential pricing mechanisms to encourage technology adoption by startups, micro and small enterprises. In addition, CSIR leverages digital platforms such as the CSIR Tech Anusandhan Portal, institutional websites, social media, podcasts, and outreach programmes to enhance the visibility of its technologies and expand industry engagement.
The initiatives undertaken by CSIR are expected to strengthen India's healthcare ecosystem by accelerating the translation of laboratory research into affordable and commercially viable healthcare products and technologies. Through technology transfer, industry partnerships and academia-industry collaboration, CSIR promotes indigenous development and manufacturing of pharmaceuticals, diagnostics, biologics and medical technologies, thereby reducing dependence on imports and supporting the objectives of Atmanirbhar Bharat. These initiatives are expected to improve the affordability and accessibility of quality healthcare, strengthen national capabilities in disease surveillance, genomics and precision medicine, and facilitate commercialization of indigenous technologies. Collectively, these efforts enhance healthcare resilience, promote innovation-led industrial growth, and improve access to affordable healthcare across the country.
This information was given by Union Minister of State (Independent Charge) for Science & Technology; Earth Sciences and Minister of State in the Prime Minister's Office, Personnel, Public Grievances and Pensions, Atomic Energy and Space, Dr. Jitendra Singh, in a written reply in the Rajya Sabha today.
Disclaimer: Curated by HT Syndication.
